

EXTENDED REPORT

Assessment of enthesitis in ankylosing spondylitis

L Heuft-Dorenbosch, A Spoorenberg, A van Tubergen, R Landewé, H van der Tempel, H Mielants, M Dougados, D van der Heijde

Ann Rheum Dis 2003;62:127–132

See end of article for authors' affiliations

Correspondence to:
Dr L Heuft-Dorenbosch,
Department of Internal
Medicine, Division of
Rheumatology, University
Hospital Maastricht, PO
Box 5800, 6202 AZ
Maastricht, The
Netherlands;
ehauf@sint.azm.nl

Accepted 24 June 2002

Objective: To assess, firstly, the validity of the enthesitis index published by Mander (Mander enthesitis index (MEI)) and, secondly, to investigate whether it is possible to define a new enthesitis index that is less time consuming to perform with at least similar or better properties.

Methods: Data from the OASIS cohort, an international, longitudinal, observational study on outcome in ankylosing spondylitis, were used. In this study, measures of disease activity, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the MEI, were assessed regularly in 217 patients. With the MEI, for each measurement period independently, a process of data reduction was performed to identify the entheses most commonly reported as painful by the patients. A more concise enthesitis index was constructed with aid of the entheses found in this way. Correlations with measures of disease activity were used to test the validity of several enthesitis indices.

Results: Reduction of the number of entheses from 66 to 13 and omitting grading of the intensity of pain resulted in an index which was named the "Maastricht Ankylosing Spondylitis Enthesitis Score" (MASES). The MASES (range 0–13) has much greater feasibility than the MEI (range 0–90). However, up to 21% of patients with a score >0 on the MEI were not identified by a score on the MASES >0. Only 2.1% of the patients with an original enthesitis score >0 had an original score on the MEI >3 (range 0–90) and it can be questioned whether a low score on the MEI index represents clinically important enthesitis. The Spearman correlation coefficient between the MASES score and the MEI was 0.90 and between the MASES and the BASDAI was 0.53 compared with a correlation of 0.59 between the MEI and the BASDAI.

Conclusions: MASES seems to be a good alternative to the MEI with much better feasibility.

In 1995, the "ASsessment in Ankylosing Spondylitis" (ASAS) working group was formed in order to select a core set for outcome assessment in ankylosing spondylitis (AS).¹ This international working group consists of clinical experts, clinical epidemiologists, representatives of the pharmaceutical industry, and representatives of patient leagues who share their expertise in the field of AS. In 1998, a definite core set was selected, to be used in various clinical settings, which consisted of different domains with specific instruments for each domain.² For example, the domains selected to evaluate disease controlling treatment are function, pain, spinal mobility, patient's global, stiffness, peripheral joints and entheses, acute phase reactants, spine and hip radiology, and fatigue. For all domains except entheses and fatigue, a specific instrument was selected.

Enthesitis is a primary clinical feature in AS. In 1987, Mander *et al* published an instrument to investigate enthesitis in AS (the Mander enthesitis index (MEI)).³ A total of 66 entheses are investigated by local pressure, and intensity of pain is graded on a 0–3 scale (0=no pain; 1=mild tenderness; 2=moderate tenderness; 3=wince or withdraw). This instrument, however, is neither widely used in daily practice nor in clinical trials. The members of the ASAS working group questioned the feasibility of the MEI. Applying the MEI is time consuming; there may be a potential discrepancy between the reaction of the patient and its interpretation by the doctor; and applying pressure on all sites in active enthesitis may be unacceptable to the patient. Therefore the ASAS working group suggested that more research should be carried out in this field before selecting an official instrument.

To assess the appropriateness of an instrument to measure outcome, all aspects of validity need to be examined. To standardise the nomenclature of validity, the OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) filter has been proposed.⁴ The three domains of the OMERACT

filter are truth (validity), discrimination (reproducibility and responsiveness), and feasibility.

To be able to relate the level of enthesitis with the overall level of disease activity, an instrument to assess disease activity should be selected. However, in AS, currently no "gold standard" exists for measuring disease activity. Objective measures such as C reactive protein (CRP) and Westergren erythrocyte sedimentation rate (ESR) correlate poorly with clinical disease activity.⁵ A self administered questionnaire has therefore been developed that better reflects clinical disease activity in AS: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). This instrument has been shown to be valid, reproducible, and responsive to change.^{6–8} Also widely used to measure disease activity is a 10 cm visual analogue scale (VAS) to be completed by the patient and by the doctor separately.


This study aimed, firstly, at assessing the validity of the MEI and, secondly, at investigating whether it is possible to modify the MEI to produce a less time consuming index with at least similar validity.

PATIENTS AND METHODS

Patients

For this study we used data from the OASIS cohort; an international, longitudinal, observational study on outcome in AS

Abbreviations: AS, ankylosing spondylitis; ASAS, ASsessment in Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MEI, Mander enthesitis index; MRI, magnetic resonance imaging; NSAIDs, non-steroidal anti-inflammatory drugs; OMERACT, Outcome Measures in Rheumatoid Arthritis Clinical Trials; VAS, visual analogue scale



Mander entheses index. Reproduced with permission of the authors and the copyright holders from reference 3. Copyright © 1987 *Annals of the Rheumatic Disease*.

with follow up visits according to a fixed protocol. Data from this cohort have been previously reported.³ Consecutive outpatients with an established diagnosis of AS according to the modified New York criteria were included in 1996. We here will report data of patients from the University Hospital Maastricht, and the Maasland Hospital Sittard, the Netherlands and the University Hospital Gent, Belgium, all secondary and tertiary referral centres. Data from baseline, one year follow up, and two year follow up will be presented. At these visits patients completed a number of questionnaires and underwent a clinical examination including the MEI.

Mander entheses index

To assess the MEI, the investigator applies pressure over 66 different entheses accessible to palpation. The patients' response to firm palpation over these entheses is noted (0=no pain; 1=mild tenderness; 2=moderate tenderness; 3=wince or withdraw). The following sites are included in the index: the nuchal crests, the manubriosternal joint, the costochondral joints, the greater tuberosity and the medial and lateral epicondyles of the humerus, the iliac crests, the anterior superior iliac spines, the greater trochanter of the femur, the medial and lateral condyles of the femur, the insertion of the Achilles tendons and plantar fascia to the calcaneus, the cervical, thoracic, and lumbar spinous processes, the ischial tuberosities, and the posterior superior iliac spines. Figure 1 shows the entheses included in the MEI. Some of the sites are scored individually whereas others are scored as a group, with the highest scoring site being recorded for the group as a whole. The sites that were grouped were the nuchal crests, the costochondral joints, the cervical, thoracic, and lumbar spinous processes. After grouping, a maximum score of 90 can be achieved.

Table 1 Baseline characteristics and scores on ASAS core set measures of the study patients (mean (SD))

	Total study group (n=162)
Male/female	112/50
Age (years)	44.9 (12.3)
Duration of complaints (years)	21.6 (12.0)
Time since diagnosis (years)	11.4 (9.2)
HLA-B27 (present/absent/no data)	105/18/39
History of IBD (present/absent)	17/145
History of uveitis (present/absent)	62/100
History of psoriasis (present/absent)	10/152
BASFI	3.7 (2.4)
VAS pain of the spine (cm)	3.5 (2.3)
Night pain (4 point Likert)	1.2 (0.8)
Chest expansion (cm)	4.2 (1.9)
10 cm Schober (cm)	2.6 (1.4)
Occiput to wall distance (cm)*	2.7 (0.0-7.5)
VAS patient global (cm)	3.4 (2.7)
Arthritis as measured by swollen joints (present/absent)	41/121
ESR (mm/1st h)*	9 (4-17)
CRP (mg/l)*	7 (6-16)
VAS doctor for disease activity (cm)	1.8 (1.8)
VAS doctor for disease activity* (cm)	1.0 (0.5-2.6)
VAS patient for disease activity (cm)	3.5 (2.6)
VAS patient for disease activity* (cm)	3.0 (1.1-5.2)
Duration of morning stiffness (min)	37 (29)

*Median (interquartile range).

ASAS, ASsessment in Ankylosing Spondylitis; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, C reactive protein.

Measures of disease activity

The BASDAI consists of six questions on fatigue, pain of the spine and hips, pain or swelling of the peripheral joints, localised tenderness as a proxy for enthesitis, and severity and duration of morning stiffness. The questions are answered on a 10 cm VAS, anchored with the labels "none" and "very severe" at either end of the first five questions, and with "0 hours" and "two hours" at either end of the question on duration of morning stiffness. The mean of the two scores for morning stiffness counts as one variable. The final score is defined by calculating the mean of the five items. Scores range from 0 (best) to 10 cm (worst). When values were missing, at most one out of six questions from the BASDAI was substituted by the patient's mean. In the case of a missing value for questions 5 or 6, both dealing with morning stiffness, the remaining question counted as the mean of questions 5 and 6.

A single item 10 cm VAS, concerning the degree of disease activity, and to be completed by both the patient and the doctor independently was anchored "no disease activity" at 0 cm and "very severe activity" at 10 cm.

The ESR was assessed by the Westergren method (mm/1st h; normal range for men 0-7, for women 0-12) and CRP by the turbidimetric method (mg/l; normal range 2-9). The lowest detection limit for CRP was 2 mg/l and patients with undetectable levels were assigned 0.

Statistical analysis

Data at baseline, one and two years' follow up were analysed independently. Initially, the doctor recorded all 66 different entheses included in the MEI without grouping. After grouping, an entheses score according to Mander was calculated for every patient. As a next stage, for each entheses the original gradation of pain on the MEI was recoded dichotomously into "no pain" or "painful". An original score of 0 was regarded as no pain; original scores ranging from 1 to 3 were regarded as painful. Only data from patients with a score on the MEI of >0 were used for developing modifications of the MEI.

Table 2 Most frequently scored enthesis points at baseline, at one year follow up, and at two year follow up in order of detection during the data reduction process

Baseline	One year follow up	Two year follow up
Proximal insertion of Achilles tendon left*	Posterior superior iliac spine left*†	5th Lumbar spinous process*†
Iliac crest left*†	7th Costochondral joint right*†	7th Costochondral joint right*†
5th Lumbar spinous process*†	1st Costochondral joint right*†	Posterior superior iliac spine left*†
7th Costochondral joint left*†	Proximal insertion of Achilles tendon left*	4th Costochondral joint left*
1st Thoracic spinous process*	4th Lumbar spinous process*	Anterior superior iliac spine right†
	9th Thoracic spinous process*	
76% of patients with MEI >0 detected	79% of patients with MEI >0 detected	83% of patients with MEI >0 detected

MEI, Mander enthesitis index.

*Included in reduced Mander enthesitis index; †included in Maastricht Ankylosing Spondylitis Enthesitis Score.

Table 3 Entheses selected in the reduced Mander enthesitis index and the concise enthesitis index, listed from head to toe

Reduced Mander enthesitis index	Concise enthesitis index
1st Costochondral joint left/right	1st Costochondral joint left/right
4th Costochondral joint left/right	
7th Costochondral joint left/right	7th Costochondral joint left/right
Posterior superior iliac spine left/right	Posterior superior iliac spine left/right
Anterior superior iliac spine left/right	Anterior superior iliac spine left/right
Iliac crest left/right	Iliac crest left/right
1st Thoracic spinous process	
4th Lumbar spinous process	
5th Lumbar spinous process	5th Lumbar spinous process
9th Thoracic spinous process	
Proximal insertion of Achilles tendon left/right	Proximal insertion of Achilles tendon left/right

Table 4 Number of patients at baseline, one year follow up, and two year follow up with a score on the Mander enthesitis index, the reduced Mander enthesitis index, and the concise enthesitis index of >0. Results are shown as number (%) of patients

	Baseline (n=149)	One year follow up (n=151)	Two year follow up (n=129)
Mander enthesitis index >0	115 (77)	103 (68)	86 (67)
Reduced Mander enthesitis index >0	98 (66)	92 (61)	81 (63)
Concise enthesitis index >0	91 (61)	83 (55)	77 (60)
Major enthesitis index >0	83 (56)	61 (40)	51 (40)

In the following analyses a process of data reduction was performed. Baseline, one year follow up, and two year follow up were analysed independently. Frequency tables were used to determine which specific enthesitis was scored painful most frequently at the specific time. This enthesitis was noted and all patients reporting this enthesitis as painful were not taken into consideration in the subsequent step. In the remaining patients, a similar analysis with use of frequency tables was performed to determine which enthesitis was scored most frequently as painful. Similarly, all patients reporting this particular enthesitis as painful were not included in subsequent steps. This process was repeated until up to 80% (arbitrarily chosen) of all patients with a score on the MEI >0 were included. If an equal amount of patients reported two different entheses as most frequently painful at the same analysis, we selected the point that was anatomically the most easy to localise. The entheses detected in this way at baseline, one year, and two years were taken together. If an enthesitis was situated on the right or left side of the body, the contralateral enthesitis was also included. Because we wanted an index as concise as possible, we decided, additionally, to decrease the

number of entheses by omitting entheses more difficult to localise and entheses neighbouring those already selected.

As a last step the MEI, and the two modified MEIs were calculated with and without gradation of the intensity of pain.

Braun *et al* recently used an enthesitis index in a study on infliximab in AS, composed of 12 entheses which are reported to be commonly affected in the inflammatory process in AS (major entheses index).⁹⁻¹¹ This major entheses index includes the iliac crests, the great trochanters of the femur, the medial and lateral condyles of the femur, the proximal insertion of the Achilles tendon and insertion of the plantar fascia to the calcaneus. We also assessed how this major entheses index performed in our study group.

Spearman's correlation was used to determine the relationship between the original MEI and its proposed modifications with disease activity as measured by the BASDAI, the "enthesitis question" of the BASDAI, patient and doctor VAS for disease activity, ESR, and CRP. To assess a possible floor effect, the number of patients with a score on the original MEI of >0 was compared with the number of patients with a score on the modified enthesitis indexes of >0.

Table 5 The number of patients missed by the major entheses index (score = 0), but with a score of >0 on the Mander entheses index

Score on Mander entheses index	Baseline*	One year follow up*	Two year follow up*
1	11	14	8
2	9	9	11
3	4	9	7
4	3	7	6
5	1	2	0
6	2	1	1
7	1	0	1
8	0	0	1
9	1	0	0
Total	32	42	35

*Number of patients.

RESULTS

Table 1 presents the patient characteristics and scores on the ASAS core set measures. Of the patients, 112/162 (69%) patients were male, mean duration of complaints was 21.6 years, established disease duration was 11.4 years. Assessment of HLA-B27 was available in 123 patients; of these patients 85% were HLA-B27 positive. Table 2 presents the most frequently scored entheses at baseline, at one year follow up, and at two year follow up. At baseline, the MEI was available for 149 patients, of whom 115 reported a score >0. By pressure on five different entheses, 87 (76%) of these 115 patients were detected. At one year follow up, the MEI was available in 151 patients, of whom 103 reported an MEI >0. By pressure on six different entheses out of 66, 81 (79%) of these 103 patients were identified. At two year follow up, the MEI was available in 129 patients, of whom 86 reported an MEI >0; five entheses identified 71 (83%) of these 86 patients. Of the total of 16 entheses selected at the three measurement periods, five appeared twice, which made a total of 11 selected different entheses. If an entheses was localised on the left or right side of the body, the entheses on the contralateral side was also included, which increased the number of entheses to 18. We named this new index the "reduced Mander entheses index".

To develop an entheses index which was as concise as possible by further reducing the number of entheses, we excluded the following entheses: L4 because L5 was included; costochondral joint 4, because costochondral joints 1 and 7 were included, and Th1 and Th9 because these are not easy to localise. Moreover L4, Th1, costochondral joint 4, and Th9 were only found in the last steps of the data reduction process and their inclusion increased the percentage of detected patients by only 4% at baseline, 6% at one year follow up, and 8% at two year follow up. The total number of entheses was now reduced to 13. We named this group of 13 entheses the "concise entheses index". Table 3 lists the entheses selected in the reduced Mander entheses index and the concise entheses index.

Table 4 presents the number and percentage of patients reporting a score more than 0 on the MEI, the reduced Mander entheses index, the concise entheses index, and the major entheses index. At baseline, 24 patients (21%) with a score >0 on the original MEI were not detected by a score >0 on the concise entheses index. At one and two years' follow up these numbers were 20 patients (19%) and nine (10%) patients, respectively. The major entheses index did not detect 32, 42, and 35 patients at baseline, one and two years' follow up with a score >0 on the MEI (table 5). Table 6 presents the mean, median, 25th–75th centiles, and range of the four different entheses indices.

To assess a possible floor effect of the MEI, table 7 presents the patients with a score of 0 on the concise entheses index with a score >0 on the MEI at baseline, one year and two

Table 6 Values for the Mander entheses index, reduced Mander entheses index without gradation, concise entheses index, and major entheses index without gradation at baseline, one and two years follow up

Entheses index	Mean (SD)	Median (25th–75th centile)	Range
Mander entheses index with gradation (range 0–90)			
Baseline	8 (11)	4 (1–10)	0–56
1 Year	6 (9)	2 (0–8)	0–47
2 Years	7 (11)	2 (0–11)	0–56
Reduced Mander entheses index without gradation (range 0–18)			
Baseline	4 (5)	2 (0–7)	0–18
1 Year	3 (5)	2 (0–7)	0–18
2 Years	4 (5)	2 (0–6)	0–18
Concise entheses index without gradation (range 0–13)			
Baseline	3 (4)	2 (0–5)	0–13
1 Year	2 (3)	1 (0–4)	0–13
2 Years	3 (4)	1 (0–5)	0–13
Major entheses index without gradation (range 0–12)			
Baseline	2 (3)	1 (0–4)	0–12
1 Year	2 (3)	0 (0–2)	0–12
2 Years	2 (3)	0 (0–3)	0–12

Table 7 The number of patients missed by the concise index (score = 0), but with a score of >0 on the Mander entheses index

Score on Mander entheses index	Baseline*	One year follow up*	Two year follow up*
1	12	5	1
2	4	5	3
3	5	5	4
4	1	2	1
5	1	1	0
6	1	1	0
7	0	0	0
8	0	1	0
Total	24	20	9

*Number of patients.

years' follow up. The total of 53 patients missed with the concise entheses index predominantly appeared to have low scores on the MEI; 44 of these 53 patients had a score on the MEI of ≤ 3 (range 0–90).

Table 8 presents the correlation between the MEI (with and without gradation), the reduced Mander entheses index (with and without gradation) the concise entheses index, and the major entheses index (with and without gradation) and the BASDAI, the entheses question of the BASDAI, ESR, CRP and the patients and the doctors' VAS for the degree of disease activity. The entheses question of the BASDAI did not show a higher correlation coefficient with the MEI (with and without gradation), the reduced Mander entheses index (with and without gradation), and the concise entheses index. Furthermore, it can be seen that the correlation with measurements of disease activity does not change significantly when the three different entheses indices are applied. On applying the concise entheses index without gradation compared with the MEI (which is graded), the correlation was only slightly decreased. We propose to call the concise entheses index without gradation the "Maastricht Ankylosing Spondylitis Entheses Score" (MASES). Figure 2 shows the entheses of the MASES.

DISCUSSION


Some remarks should be made about applying the OMERACT filter to the entheses index by Mander *et al.* As far as we know,

Table 8 Spearman correlation between Mander enthesitis index, reduced Mander index, concise enthesitis index with and without gradation versus measures of disease activity

	Mander enthesitis index	Mander enthesitis index without gradation	Reduced Mander enthesitis index	Reduced Mander enthesitis index without gradation	Concise enthesitis index with gradation	Concise enthesitis index without gradation (MASES)	Major enthesitis index without gradation
BASDAI*	0.59	0.58	0.57	0.56	0.54	0.53	0.49
Enthesis question BASDAI*	0.57	0.56	0.55	0.54	0.53	0.51	0.41
VAS doctor*	0.30	0.27	0.29	0.27	0.24	0.22	0.21
VAS patient*	0.47	0.45	0.48	0.47	0.45	0.44	0.37
CRP†	0.07	0.06	0.06	0.05	0.05	0.04	0.02
ESR†	0.06	0.07	0.07	0.07	0.05	0.04	0.07

*Correlation coefficients significant at the $p < 0.01$ level; †correlation coefficients not significant.

BASDAI, Bath Ankylosing Spondylitis Disease Activity; VAS, visual analogue scale; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesis Score.

**Figure 2** MASES.

no reports exist in which the MEI is correlated with histological proof or radiological signs (for example, magnetic resonance imaging (MRI) or ultrasound) of enthesitis. Unfortunately, we were not able to assess this aspect in our study. However, there are studies investigating the correlation between clinical signs of enthesitis (swelling or/and pain) and imaging methods such as MRI or ultrasonography. MRI may show swelling of the enthesitis and the peritendinous soft tissue swelling, distension of adjacent bursae by fluid collection, and oedema of the bone near the insertion. Ultrasonography may show the following signs of enthesitis: thickening of the tendon insertion, intratendinous focal changes, calcific deposits in the insertions, and periosteal changes. Recently, Marzo Ortega *et al* performed a descriptive longitudinal study in which the efficacy of etanercept in the treatment of resistant spondyloarthritis was assessed in 10 patients.¹² In their study clinical enthesitis was investigated by

clinical assessment of 78 entheses and by a patient VAS. In the nine patients with clinical enthesitis, clinical enthesitis resolved completely in seven patients and improved in two patients. In these nine patients, there were 44 MRI detectable enthesal lesions, of which 86% resolved completely or improved. The concomitant amelioration of both MRI findings and clinical findings suggests that a clinical measure for enthesitis does indeed depict enthesitis; however, the study was not designed to assess the validity of a clinical measure to assess entheses. Lehtinen *et al* studied 31 consecutive patients with spondyloarthritis for the presence of enthesiopathy in the legs both clinically and with ultrasonography.¹³ Sonography detected inflammatory lesions in 44 entheses of 20 patients, clinical examination detected 56 symptomatic entheses in 20 patients suspected of enthesitis. In 21 entheses, both examinations were positive.

A measure to assess entheses should distinguish enthesitis from other causes of (joint) pain such as arthritis. Mander *et al* developed their enthesitis index in a study in which only patients with AS without peripheral arthritis were included.³ In our patients peripheral arthritis, as measured by the presence of at least one swollen joint, was present in 25% of patients. In the process of developing the MASES, the only enthesitis included close to a peripheral joint, was the proximal insertion of the Achilles tendon. Thus less confounding with pain due to peripheral arthritis occurs with the MASES than with the MEI.

An enthesitis index is meant to measure the severity of enthesitis. Severity encompasses both the intensity and extent of enthesitis. It is not known whether the patients' response correlates with the intensity of enthesitis and as stated in the original article by Mander "it is not known whether the severity or simply the presence of tenderness over the entheses is important".³ Interpretation of the degree of the patients' response reflected in grades can increase both inter- and intraobserver bias. In joint counts it has been proved that gradation did not improve the performance of the scores and is therefore not recommended.¹⁴ Without the gradation, the MEI is easier to perform, and in our study grading did not improve the correlation with measures of disease activity.

The MEI is not very practical to apply clinically because of its extensiveness. This study shows that a reduction of the entheses index to 13 entheses instead of 66 still provides reasonable assessment of the entheses.

On 53 visits, patients who originally had a score on the MEI > 0 are missed with the MASES (table 7). Most of these patients had a low score on the MEI. It might be questioned whether a low score on the MEI represents clinically important enthesitis. However, this indicates that there might be some floor effect in the MASES. In our view the non-detection of a few patients is more than balanced by the enormous gain in feasibility. In many trials, including two

recently published large trials on non-steroidal anti-inflammatory drugs (NSAIDs),^{15,16} no measure for entheses is included, illustrating the lack of acceptability of the MEI. This in contrast with the importance placed on entheses by the ASAS group and the opinion that enthesitis can be seen as the cornerstone of the site of inflammation in AS.^{9,17,18}

The fourth question of the BASDAI can be considered to be an enthesiopathy VAS. It might be questioned why this patient VAS is not used to evaluate enthesitis rather than an index used by the doctor. However, it is usual for the doctor to differentiate between enthesal pain and articular, muscular, or other causes of pain; this can be more difficult for patients. Therefore a combination of patient and doctor assessment of enthesitis would be preferable.

The index should discriminate not only between active and inactive disease and between groups of patients but also within individual patients. Only a small study to investigate the discriminative ability of the MEI is reported in the original paper, in which the MEI is compared in patients with AS with and without NSAID treatment. So far we have not tested the discriminative ability of the full MEI, the reduced Mander index, and the MASES. We contacted many authors of published and unpublished trials in AS. None of these had included the MEI in their studies. Therefore we make a plea that the MEI is included in studies so that the discriminative power of the various enthesitis scores can be tested. New trials on tumour necrosis factor blockade treatment could provide this information, especially if MRI of the spine is carried out concomitantly to demonstrate sites of inflammation. While awaiting further validation of the MASES, we recommend its use as it seems to be a good alternative.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Dutch League Against Rheumatism, grant number NR-99-1-302.

Authors' affiliations

L Heuft-Dorenbosch, A Spoorenberg, A van Tubergen, R Landewé, D van der Heijde, Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
H van der Tempel, Department of Rheumatology, Maasland Hospital Sittard, The Netherlands
H Mielants, Department of Rheumatology, University Hospital Gent, Gent, Belgium
M Dougados, Department of Rheumatology, Hospital C6chin, Paris, France

REFERENCES

- 1 **van der Heijde D**, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. *J Rheumatol* 1997;24:2225-9.
- 2 **van der Heijde D**, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. *J Rheumatol* 1999;26:945-7.
- 3 **Mander M**, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis. *Ann Rheum Dis* 1987;46:197-202.
- 4 **Boers M**, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial]. *J Rheumatol* 1998;25:198-9.
- 5 **Spoorenberg A**, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. *J Rheumatol* 1999;26:980-4.
- 6 **Garrett S**, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286-91.
- 7 **Jones SD**, Calin A, Steiner A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. *J Rheumatol* 1996;23:407.
- 8 **Calin A**, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? *Rheumatology (Oxford)* 1999;38:878-82.
- 9 **Ball J**. Enthesopathy of rheumatoid and ankylosing spondylitis. *Ann Rheum Dis* 1971;30:213-23.
- 10 **Gerster JC**. Plantar fasciitis and Achilles tendinitis among 150 cases of seronegative spondylarthritis. *Rheumatol Rehabil* 1980;19:218-22.
- 11 **Braun J**, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;359:1187-93.
- 12 **Marzo Ortega H**, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. *Arthritis Rheum* 2001;44:2112-17.
- 13 **Lehtinen A**, Taavitsainen M, Leirisalo Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. *Clin Exp Rheumatol* 1994;12:143-8.
- 14 **Prevo ML**, van Riel PL, van 't Hof MA, van Rijswijk MH, van Leeuwen MA, Kuper HH, et al. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. *Br J Rheumatol* 1993;32:589-94.
- 15 **Dougados M**, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. *Rheumatology (Oxford)* 1999;38:235-44.
- 16 **Dougados M**, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. *Arthritis Rheum* 2001;44:180-5.
- 17 **McGonagle D**, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. *Lancet* 1998;352:1137-40.
- 18 **McGonagle D**, Khan MA, Marzo Ortega H, O'Connor P, Gibbon W, Emery P. Enthesitis in spondylarthropathy. *Curr Opin Rheumatol* 1999;11:244-50.